Eli Lilly Settles Zyprexa Claims

Law360, New York (January 4, 2007, 12:00 AM EST) -- Eli Lilly & Co. has reached settlements in about 18,000 claims that the company didn’t properly disclose that patients taking Zyprexa, the company’s schizophrenia drug, were at risk to develop diabetes and other disorders, the company said Thursday.

The settlements will resolve the vast majority of the remaining claims over embattled Zyprexa. The settlement agreements follow a master settlement agreement Lilly entered into in June 2005 that paid about $700 million to cover approximately 8,000 claimants in the U.S. Since then, it has settled about 2,500...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.